Targeted Disease(s):
Lung Cancer
Purpose of Study:
What is the purpose of this study?: A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Study Dates:
December 1, 2024 - May 23, 2029
Type of Study:
Post-Market
Study Location:
Nationwide
Funding Source:
J&J
Contact:
[email protected]
844-434-4210
ClinicalTrails.gov Identifier:
NCT06667076
